CBD(cyclophohamide,bortezomib,dexamethasone) induction followed by autologous stem cell transplantation for patients with newly diagnosed multiple myeloma

Trial Profile

CBD(cyclophohamide,bortezomib,dexamethasone) induction followed by autologous stem cell transplantation for patients with newly diagnosed multiple myeloma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 May 2016

At a glance

  • Drugs Bortezomib (Primary) ; Cyclophosphamide; Dexamethasone
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Jan 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top